103 Carnegie Center
Suite 300
Princeton, NJ 08540
ph: 215-554-3530
info
news
October 26, 2011 - Eleison Licenses Glufosfamide to Daewoong Pharmaceuticals for Korean Market
September 9, 2011 - Eleison Announces the Appointment of Three New Members to its Science Advisory Board
May 26, 2011 - Eleison Selects CRO Pharm-Olam International to Manage Phase III Clinical Study of Glufosfamide for Pancreatic Cancer. Pharm-Olam to Make $2 Million Investment in Eleison.
April 28, 2011 - Glufosfamide Granted Orphan Drug Designation in Europe
April 7, 2011 - Eleison Pharmaceuticals Honors the Life of Dr. Baruch S. Blumberg
January 17, 2011 - Eleison Appoints Dr. Howard Hochster to its Science Advisory Board
December 16, 2010 - Eleison Appoints Dr. Murray Korc to its Science Advisory Board
December 1, 2010 - Eleison Pharmaceuticals Interviewed by New York Times
November 2, 2010 - Eleison Announces Notice of Award of U.S. Qualifying Therapeutic Discovery Grants
July 7, 2010 - Eleison Appoints Dr. Baruch Blumberg to its Science Advisory Board
May 26, 2010 - Eleison Announces Agreement with FDA on a Special Protocol Assessment (SPA) for a Phase III Clinical Trial of Glufosfamide in Pancreatic Cancer
October 15, 2009 - Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
103 Carnegie Center
Suite 300
Princeton, NJ 08540
ph: 215-554-3530
info
